Fennec Pharmaceuticals (FENC) CCO receives 168-share award, holds 21,183

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans reported an equity compensation transaction involving the company’s common shares. On the reported date, Evans acquired 168 common shares through a grant, award, or other acquisition, with no cash price shown for the shares.

Following this award, Evans directly holds 21,183 common shares. A footnote explains that the 168 shares represent shares released from restriction from an award originally granted on March 28, 2025, indicating this is part of a previously approved compensation arrangement rather than an open‑market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Evans Terry L

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	168	$0.00	--

Holdings After Transaction: Common Shares — 21,183 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity award shares: 168 common shares Post-transaction holdings: 21,183 common shares Award grant date: March 28, 2025 +1 more

4 metrics

Equity award shares 168 common shares Grant, award, or other acquisition on 2026-06-30

Post-transaction holdings 21,183 common shares Direct holdings following the reported transaction

Award grant date March 28, 2025 Original award from which restricted shares were released

Transaction price $0.0000 per share Reported price for the 168 granted shares

Key Terms

Grant, award, or other acquisition, Common Shares, shares released from restriction, Form 4

4 terms

Grant, award, or other acquisition financial

"transaction code description is "Grant, award, or other acquisition" for the 168 shares"

Common Shares financial

"The security title for the transaction is listed as "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

shares released from restriction financial

"Footnote states these represent shares released from restriction from shares awarded 3/28/2025"

Form 4 regulatory

"Insider transaction data is presented as a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:39 PM Accepted by SEC EDGAR 07/01/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans Terry L

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	06/30/2026		A		168	A	$0	21,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Terry Evans	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for Terry L. Evans?

Fennec Pharmaceuticals reported that Chief Commercial Officer Terry L. Evans acquired 168 common shares through an equity award. The filing characterizes this as a grant, award, or other acquisition, reflecting compensation rather than an open-market stock purchase or sale.

How many Fennec Pharmaceuticals (FENC) shares does Terry L. Evans hold after this Form 4?

After this transaction, Terry L. Evans directly holds 21,183 common shares of Fennec Pharmaceuticals. This total includes the 168 shares released from restriction, which were part of a previously granted equity award dated March 28, 2025.

Was the Fennec Pharmaceuticals (FENC) insider transaction an open-market buy or sell?

The transaction was not an open-market buy or sell. It is reported under code A as a grant, award, or other acquisition of 168 common shares, linked to restricted shares released from a prior equity award granted on March 28, 2025.

What does the footnote in the Fennec Pharmaceuticals (FENC) Form 4 explain?

The footnote explains that the 168 common shares represent shares released from restriction from shares awarded on March 28, 2025. This indicates the transaction reflects vesting or release of previously granted restricted stock rather than a new market transaction.

What role does Terry L. Evans hold at Fennec Pharmaceuticals (FENC)?

Terry L. Evans serves as Chief Commercial Officer at Fennec Pharmaceuticals. The Form 4 shows a compensation-related acquisition of 168 common shares, bringing Evans’ directly held position to 21,183 common shares after the reported transaction.